Rational Vaccines, Inc.

3:00 PM - 3:15 PM (PDT), Monday, June 13, 2022
We are an investigational stage infectious disease company focused on combating all diseases resulting from herpes simplex virus 1 (HSV-1) and herpes simplex virus 2 (HSV-2) infections.

Using our proprietary technology, we are developing rationally engineered, live attenuated viral immunotherapeutic and prophylactic vaccine candidates. Our aim is to help improve lives by reducing the suffering of those infected and reduce the spread of the virus. Our goal is to revolutionize the treatment, prevention, and diagnosis of herpes and herpes-related diseases worldwide. We envision a future where the world is free of herpes.

Focused on ending aglobal pandemic.
The herpes simplex virus (HSV) is one of world’s most prevalent infections, negatively impacting the health of billions of people of all ages—and it can be spread when there are no symptoms or sores. Infected individuals are frequently asymptomatic at early stages, and at high risk of transmission. Yet herpes is not routinely scr
Company Type:
Privately Funded Company
Company HQ State:
Massachusetts
Company HQ Country:
United States
Year Founded:
2017
Main Therapeutic Focus:
Lead Product in Development:
HSV-2 vaccine (therapeutic, prophylactic)
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
2